ArticleInternational journal of molecular sciences2022

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.

Eline A M Ruigrok et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.